Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

Background: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest. Methods: In this phase II trial, patients with metastatic platinum-refractory UC molecularly selected for p16 loss and intact Rb by tumour immunohistochemistry received palbociclib 125 mg p.o. daily for 21 days of a 28-day cycle. Primary endpoint was progression-free survival at 4 months (PFS4) using a Simon’s two-stage design. Next-generation sequencing including Rb pathway alterations was conducted. Results: Twelve patients were enrolled and two patients (17%) achieved PFS4 with insufficient activity to advance to stage 2. No responses were seen. Median PFS was 1.9 months (95% CI 1.8–3.7 months) and median overall survival was 6.3 months (95% CI 2.2–12.6 months). Fifty-eight percent of patients had grade ≥3 hematologic toxicity. There were no CDKN2A alterations found and no correlation of Rb pathway alterations with clinical outcome. Conclusions: Palbociclib did not demonstrate meaningful activity in selected patients with platinum-refractory metastatic UC. Further development of palbociclib should only be considered with improved integral biomarker selection or in rational combination with other therapies

Electrical transport of bottom-up grown single-crystal Si 1-xGex nanowire

10.1088/0957-4484/19/22/225203Nanotechnology1922-NNOT

Study on the synthesis of high quality single crystalline Si1-x Gex nanowire and its transport properties

10.1063/1.2772665Applied Physics Letters917-APPL

Synthesis and transistor performances of high quality single crystalline vapor-liquid-solid grown Si1-xGex nanowire

10.1109/NANO.2007.46011372007 7th IEEE International Conference on Nanotechnology - IEEE-NANO 2007, Proceedings45-4

Complementary metal-oxide-semiconductor compatible Al-catalyzed silicon nanowires

10.1149/1.2716304Electrochemical and Solid-State Letters10611-13ESLE

Effect of annealing on the composition and structure of HfO2 and nitrogen-incorporated HfO2

10.1016/j.tsf.2004.05.030Thin Solid Films462-463SPEC. ISS.90-95THSF

Doping of Al-catalyzed vapor-liquid-solid grown Si nanowires

Materials Research Society Symposium Proceedings101866-71MRSP

High quality single crystal Al-catalyzed Si nanowire

10.1149/1.2789208ECS Transactions3309-1

Germanium p- & n-MOSFETs fabricated with novel surface passivation (plasma-PH 3 and thin AlN) and TaN/HfO 2 gate stack

Technical Digest - International Electron Devices Meeting, IEDM307-310TDIM